Table 1.
Patient and treatment characteristics of the patient cohort at BLV discontinuation.
| Patient characteristics | P1 | P2 | P3 | P4 | P5 | P6 | P7 |
|---|---|---|---|---|---|---|---|
| Sex (M/F) | F | M | F | F | M | M | F |
| Age (years) | 68 | 53 | 40 | 31 | 53 | 54 | 37 |
| Disease stage | |||||||
| Fibrosis (METAVIR) | F4 | F4 | F1 | F0/F1∗ | F2 | F4 | F4 |
| Liver stiffness (kPa) | 12.1 | 28.9 | 8.5 | 5.5 | 10.9 | 23.3 | 19 |
| Cirrhosis (yes/no) | (+) | (+) | (-) | (-) | (-) | (+) | (+) |
| Portal hypertension (yes/no) | (-) | (+) | (-) | (-) | (-) | (-) | (+) |
| Treatment | |||||||
| Duration of BLV treatment (weeks) | 141 | 60 | 51 | 124 | 46 | 67 | 80 |
| Duration of HDV-RNA suppression (weeks) | 39 | 12 | 24 | 69 | 29 | 31 | 60 |
| NA treatment (ETV/TDF) | TDF | ETV | TDF | TDF | ETV | TDF | ETV |
| IFN cotherapy (yes/no) | (-) | (-) | (-) | (+) | (+) | (-) | (-) |
| Virology | |||||||
| HDV genotype | 1 | 1 | 1 | 1 | Unknown | 1 | 1 |
| HDV-RNA prior treatment (log10 copies/ml) | 6.77 | 4.08 | 3.36 | 7.20 | 7.15 | 3.11 | 2.00 |
| HBeAg (positive/negative) | (-) | (-) | (-) | (+) | (-) | (-) | (-) |
| HBsAg (log10 IU/ml) | 4.03 | 3.22 | 3.56 | 4.37 | 4.05 | 3.09 | 3.08 |
| Biochemistry | |||||||
| Platelet count (G/L) | 220 | 110 | 173 | 288 | 246 | 180 | 76 |
| Bilirubin (mg/dl) | 0.34 | 0.82 | 0.80 | 0.50 | 1.74 | 0.54 | 0.53 |
| ALT (U/L) | 22 | 31 | 33 | 214† | 85 | 53 | 24 |
| Albumin (g/dl) | 35.8 | 48.8 | 47.0 | 38.8 | 45.7 | 45.8 | 48.7 |
ALT, alanine aminotransferase; BLV, bulevirtide; ETV, entecavir; F, female; IFN, interferon; M, male; P, patient; TDF, tenofovir disoproxile fumarate.
∗
No biopsy was performed in this patient. Fibrosis stage was estimated based on liver stiffness.
†
The patient underwent continuous interferon treatment at BLV discontinuation.